The H5N1 virus transmission to human has been observed since 1997, but there has been experience of the subtype N1 at least since 1918. However, scientists showed that the N1 and N2 subtypes could evolve into variants under drug stress. Therefore, our initiative is going to study the impact of point mutation on drug resistance. The goal is to screen a large set of compounds against the same target, the influenza A neuraminidase, with various structures predicted from homology methods thanks to grid infrastructure.

WISDOM initiative aims to demonstrate the relevance and the impact of the grid approach to address drug discovery for neglected and emergent diseases. The acronyme WISDOM, for Wide In Silico Docking On Malaria, comes from the first screening experiment at a large scale against malaria and is now used as a generic name for the initiative.